Oxlumo
Payments companies reported to CMS as associated with Oxlumo. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Oxlumo, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Oxlumo
These are the largest totals companies reported as associated with Oxlumo. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Joshua Zaritsky | Phoenix, AZ | Pediatric Nephrology | $46,495.41 |
| David Hooper | Salt Lake City, UT | Pediatric Nephrology | $17,750.29 |
| David Goldfarb | New York, NY | Nephrology (Internal Medicine) | $13,461.47 |
| Kyle Wood | Birmingham, AL | Urology | $10,722.10 |
| Yasir Qazi | Orange, CA | Nephrology (Internal Medicine) | $8,994.04 |
| John Quigley | Chicago, IL | Hematology (Internal Medicine) | $5,791.70 |
| Michael Somers | Boston, MA | Pediatric Nephrology | $5,714.00 |
| Tej Mattoo | Detroit, MI | Pediatric Nephrology | $5,427.74 |
| Jeffrey Saland | New York, NY | Pediatric Nephrology | $5,320.98 |
| Tarek Alhamad | Saint Louis, MO | Nephrology (Internal Medicine) | $4,447.72 |
Prescribed Oxlumo?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.